Potent Antifungal Activity of Penta-O-galloyl-β-d-Glucose against Drug-Resistant Candida albicans, Candida auris, and Other Non-albicans Candida Species.

ABSTRACT: Among fungal pathogens, infections by drug-resistant Candida species continue to pose a major challenge to healthcare. This study aimed to evaluate the activity of the bioactive natural product, penta-O-galloyl-β-d-glucose (PGG) against multidrug-resistant (MDR) Candida albicans, MDR Candida auris, and other MDR non-albicans Candida species. Here, we show that PGG has a minimum inhibitory concentration (MIC) of 0.25-8 μg mL^-1 (0.265-8.5 μM) against three clinical strains of C. auris and a MIC of 0.25-4 μg mL^-1 (0.265-4.25 μM) against a panel of other MDR Candida species. Our cytotoxicity studies found that PGG was well tolerated by human kidney, liver, and epithelial cells with an IC₅₀ > 256 μg mL^-1

SUBMITTER: Marquez L 

PROVIDER: S-EPMC10496123 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature